The Company is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics. The Company was founded on April 16 2007.
and its shares are listed on KOREA NEW EXCHANGE(KONEX) on July 21, 2014.
Headquarters
5 Gaepo-Ro 34-Gil, Gangnam-Gu
Seoul; Seoul;
Contact Details: Purchase the Abion Inc. report to view the information.
Website: http://www.abionbio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service